Synlogic_Logo_Blue.png
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
02 févr. 2024 12h00 HE | Synlogic, Inc.
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study ...
Synlogic_Logo_Blue.png
Synlogic Provides Corporate Update and Outlook for 2024
04 janv. 2024 07h00 HE | Synlogic, Inc.
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1...
Synlogic_Logo_Blue.png
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
07 déc. 2023 07h00 HE | Synlogic, Inc.
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE...
Synlogic_Logo_Blue.png
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
08 juin 2023 06h45 HE | Synlogic, Inc.
CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will...
Synlogic_Logo_Blue.png
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
29 mars 2023 06h40 HE | Synlogic, Inc.
– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...
Synlogic_Logo_Blue.png
Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
20 mars 2023 06h55 HE | Synlogic, Inc.
CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, announced that positive data from the...
Synlogic_Logo_Blue.png
Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
07 mars 2023 06h57 HE | Synlogic, Inc.
– Podium presentation on Phase 2 phenylketonuria (PKU) data – – Poster presentations on Phase 1 homocystinuria (HCU) data and HCU preclinical data – CAMBRIDGE, Mass., March 07, 2023 (GLOBE...
Synlogic_Logo_Blue.png
Synlogic Provides Corporate Update and Outlook for 2023
05 janv. 2023 06h58 HE | Synlogic, Inc.
Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023 Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU) Cash runway expected into H2 2024 ...
Synlogic_Logo_Blue.png
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
30 nov. 2022 16h15 HE | Synlogic, Inc.
Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA...
Synlogic_Logo_Blue.png
Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)
23 août 2022 07h00 HE | Synlogic, Inc.
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...